Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Arna H. Arnardottir"'
Autor:
Sonia Roldan Munoz, Douwe Postmus, Sieta T. de Vries, Arna H. Arnardottir, İlknur Dolu, Hans Hillege, Peter G. M. Mol
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2021)
Objective: The aim of this study was to compare the importance that patients with type 2 diabetes mellitus from the Netherlands and Turkey attach to certain drug effects of oral anti-diabetic drugs.Methods: Data were collected through a cross-section
Externí odkaz:
https://doaj.org/article/da762d60668a412fbb3fb94a2d199189
Autor:
Sonia Roldan Munoz, Douwe Postmus, Sieta T. de Vries, Arna H. Arnardottir, İlknur Dolu, Hans Hillege, Peter G. M. Mol
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 11 (2021)
FRONTIERS IN PHARMACOLOGY
Frontiers in Pharmacology, 11:617409. Frontiers Media SA
Frontiers in Pharmacology, Vol 11 (2021)
FRONTIERS IN PHARMACOLOGY
Frontiers in Pharmacology, 11:617409. Frontiers Media SA
Objective: The aim of this study was to compare the importance that patients with type 2 diabetes mellitus from the Netherlands and Turkey attach to certain drug effects of oral anti-diabetic drugs.Methods: Data were collected through a cross-section
Autor:
Hans-Georg Eichler, Pieter A. de Graeff, Arna H. Arnardottir, Flora M. Haaijer-Ruskamp, Sabine M. J. M. Straus, Peter G. M. Mol
Publikováno v:
British Journal of Clinical Pharmacology. 72:490-499
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • The safety profile of new drugs is not well known at the time of market approval and serious safety issues are regularly identified for marketed drugs. • Drugs intended to meet an unmet medical need can
Autor:
Peter G. M. Mol, Sabine M. J. M. Straus, Patrick J. Vrijlandt, Ruben G. Duijnhoven, Flora M. Haaijer-Ruskamp, Domenico Motola, Petra Denig, Pieter A. de Graeff, Arna H. Arnardottir
Publikováno v:
Drug safety, 36(11), 1105-1115. Adis International Ltd
Drug Safety, 36(11), 1105-1115. Adis
Drug Safety, 36(11), 1105-1115. ADIS INT LTD
Drug Safety, 36(11), 1105-1115. Adis
Drug Safety, 36(11), 1105-1115. ADIS INT LTD
Background At time of approval, knowledge of the full benefit risk of any drug is limited, in particular with regards to safety. Post-approval surveillance of potential drug safety concerns is recognized as an important task of regulatory agencies. F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3b85ac9c8dddb51c26c9eade66e7468
http://hdl.handle.net/11585/203016
http://hdl.handle.net/11585/203016
Autor:
Peter G. M. Mol, Flora M. Haaijer-Ruskamp, Arna H. Arnardottir, Sabine M. J. M. Straus, Pieter A. de Graeff
Publikováno v:
Drug safety. 34(11)
Background: Knowledge on the safety of new medicines is limited at the time of market entry. Nearly half of all drugs used to treat HIV registered in the EU required ≥1 Direct Healthcare Professional Communication (DHPC) in the past 10 years for sa
Autor:
Arna H, Arnardottir, Flora M, Haaijer-Ruskamp, Sabine M J, Straus, Hans-Georg, Eichler, Pieter A, de Graeff, Peter G M, Mol
Publikováno v:
British journal of clinical pharmacology. 72(3)
Regulatory requirements for new drugs have increased. Special approval procedures with priority assessment are possible for drugs with clear 'unmet medical need'. We question whether these Exceptional Circumstances (EC) or Conditional Approval (CA) p
Autor:
M E van der Elst, Mirjam J. Knol, Diederik E. Grobbee, G. Stefansdottir, M L De Bruin, Arna H. Arnardottir, Hubert G. M. Leufkens
Publikováno v:
Europe PubMed Central
Clinical Pharmacology & Therapeutics, 91(5), 872-880. Nature Publishing Group
Clinical Pharmacology & Therapeutics, 91(5), 872-880. Nature Publishing Group
This study was aimed at assessing the extent of safety learning from data pertaining to other drugs of the same class. We studied drug classes for which the first and second drugs were centrally registered in the European Union from 1995 to 2008. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6546e58bb2930e83bacb7e14c68266d5
http://europepmc.org/abstract/med/22453192
http://europepmc.org/abstract/med/22453192